Inactive Instrument
ReNeuron Group plc Stock
Stocks
RENE
GB00BF5G6K95
Biotechnology & Medical Research
OTC Markets Traded
| 24-02-06 | RENEURON ISSUES ADMINISTRATION WARNING | AQ |
| 23-11-27 | Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™ | EQ |
| 23-11-16 | ReNeuron : Interim Statement 2023 | PU |
| 23-11-07 | ReNeuron : Presentation | PU |
| 23-07-24 | ReNeuron : 24 July 2023 – Notice of Annual General Meeting | PU |
| 1 day | -2.17% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2025-03-23 |
| Director | Title | Age | Since |
|---|---|---|---|
Iain Ross
CHM | Chairman | 72 | 2021-06-30 |
| Director/Board Member | 63 | 2021-07-13 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/12/23 | Buy | Chief Financial Officer | 52,332 | 0.0915% | ||
| 6/16/23 | Buy | Director | 150,000 | 0.2624% | ||
| 6/16/23 | Buy | Chairman | 150,000 | 0.2624% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.17% | -11.18% | - | - | 2.58M | |
| +0.11% | +1.98% | -0.04% | +9.69% | 46.18B | |
| -1.12% | +3.54% | +42.71% | +25.84% | 44.35B | |
| -3.04% | -6.10% | +335.86% | +501.23% | 42.21B | |
| -0.74% | +2.64% | +5.61% | +75.14% | 40.19B | |
| -0.50% | -0.77% | +11.86% | +40.41% | 29.83B | |
| -0.46% | +5.00% | +23.00% | +118.70% | 17.17B | |
| -0.97% | -9.38% | - | - | 15.7B | |
| -0.57% | +7.78% | +21.76% | +38.08% | 15.32B | |
| -3.28% | -0.95% | -6.34% | -37.29% | 13.09B | |
| Average | -1.27% | +1.67% | +54.30% | +96.47% | 29.34B | |
| Weighted average by Cap. | -1.11% | +1.63% | +69.64% | +117.22% |
Employees
26
